Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Cyclo Therapeutics, Inc. CYTHW NASDAQ

NASDAQ Capital Marke • Healthcare • Drug Manufacturers - Specialty & Generic • US • USD

SharesGrow Score
47/100
2/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Cyclo Therapeutics, Inc. (CYTHW) — Analyst outlook / Analyst consensus target is. Based on 1 analyst ratings, the consensus is bullish — 1 Buy.

CYTHW Analyst Ratings

Buy
1
Ratings
1 Buy
Based on 1 analysts giving stock ratings to Cyclo Therapeutics, Inc. in the past 3 months
Rating breakdown
Buy
1 100%
100%
Buy
1 analysts
0%
Hold
0 analysts
0%
Sell
0 analysts

People Also View

LLY
LLY
Eli Lilly and Company
$905.13
-1.88%
 JNJ
JNJ
Johnson & Johnson
$238.67
-0.60%
 ABBV
ABBV
AbbVie Inc.
$208.43
-0.87%
 RHHBF
RHHBF
Roche Holding AG
$415.00
-0.84%
 RHHBY
RHHBY
Roche Holding AG
$50.99
-0.08%
 AZN
AZN
AstraZeneca PLC
$201.21
-1.55%
 NVS
NVS
Novartis AG
$152.08
-0.85%
 MRK
MRK
Merck & Co., Inc.
$117.90
-1.72%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message